Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 21, Issue 1, 2009, Pages 102-103

  Anghelescu, Ion ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

9 HYDROXY RISPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG; VARENICLINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; CANNABIS ADDICTION; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG TOLERABILITY; GRANDIOSE DELUSION; HUMAN; LETTER; NEGATIVE SYNDROME; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING CESSATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 64849088882     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2009.21.1.102     Document Type: Letter

References (4)

1. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; CD00103
2. Freedman R: Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007; 164:1269
3. Rollema H, Coe JW, Chambers LK, et al: Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007; 28:316-325
4. Adams CE, Stevens KE: Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Front Biosci 2007; 12:4755-4772